Immunotech Laboratories Inc – Der Geheimtipp? - 500 Beiträge pro Seite

[mcmoon]

Es ist an der Zeit auch hier bie WO eine interessante Biotech-Firma bekannt zu machen. Immunotech Laboratories! Meiner Meinung nach ein Unternehmen mit riesigem Potential... und sehr guten News die vergangenen Wochen und Monate:

Hier einige Links, die einen Einblick gewähren:

http://www.immunotechlab.com


http://yahoo.brand.edgar-online.com/default.aspx?companyid=8…


http://www.youtube.com/watch?v=uCjNAf30aeo


http://www.youtube.com/watch?v=D0SvkO_jMK4


http://www.evaluatepharma.com/Universal/View.aspx?type=Story…


http://www.evaluatepharma.com/Universal/View.aspx?type=Story…


http://investorshub.advfn.com/Immunotech-Laboratories-Inc-IM…


http://www.ad-hoc-news.de/immunotech-laboratories-announces-…

http://zhabilov.tumblr.com/

http://finance.boston.com/boston/news/read/23364004/immunote…

http://finance.boston.com/boston/news/read/23390001/dr._oz

[mcmoon]

!

Dieser Beitrag wurde von CloudMOD moderiert. Grund: ohne nachvollziehbarer Quellenagabe

[mcmoon]

Ein Patent mit immensen Möglichkeiten?

http://www.immunotechlab.com/?wpdmact=process&did=NS5ob3RsaW…

[mcmoon]

Bo Linton ein Mann mit beeindruckender Vita – nun Executive Director bei Immunotech:

http://investing.businessweek.com/research/stocks/people/per…

Mr. Bo Linton serves as Principal Executive Officer, President, Chief Financial Officer and Principal Accounting Officer of GDT Tek Inc. Mr. Linton served as the Chief Executive Officer and President of 5G Wireless Communications Inc. (Clean Energy & Power Inc.) since December 2008 until October 16, 2009 and also served as its Secretary. Mr. Linton served as President of Magnegas Corporation from March 2007 to July 3, 2008. Mr. Linton served as President of Seamless Tek Labs, Inc. (Seamless Skyy-fi Inc.), a subsidiary of Seamless Corp. (formerly Seamless Wi-Fi Inc.) from March 2005 to October 2005. From 2001 to 2003, Mr. Linton served as Writer/Director/Producer and Lead Actor for feature entitled, "Ronny Camaro and Seven Angry Women." Time Warner and Pay-Per-View. In 1998, he founded International Capital Group Inc. In November 2005, Mr. Linton founded Carbon Jungle and served as its President and Chief Executive Officer. During 2006, Mr. Linton served as a Co-executive Producer of the feature film Living Luminaries. Mr. Linton served as Chairman of the Board of Berserker Entertainment Inc., from 2001 to 2003. He serves as a Director of Steriwave-GDT Tek. He has been a Director of Immunotech Laboratories, Inc., since October 10, 2012. He has been a Director of Alpha Wireless Broadband Inc., since March 2, 2005. He served as a Director of Seamless Wi-fi Inc. since March 2, 2005. He served as Director of Magnegas Corporation from March 2007 to July 3, 2008. He served as Director of GDT Tek Inc. (Seamless Corp). since March 2, 2005. He served as a Director of 5G Wireless Communications Inc. from December 2008 to October 16, 2009. Mr. Linton received his Bachelor of General Studies from Louisiana State University in 1994 and some of his studies included; Finance, Computer Science, Computer Programming, Real Estate, Speech, Theater and Business Law.

[mcmoon]

Bo Linton zu Gast bei "Undiscovered Companies"

ein interessantes Video:
http://firstpost.com/topic/disease/cancer-undiscovered-compa…

[mcmoon]

Da Immunotech Laboratories bis dato noch an keinem deutschen Börsenplatz gehandelt wird, hier gibts nicht nur den Kurs, sondern auch den aktuellen Newsflow und alles Wissenswerte auf einen Blick:

http://www.otcmarkets.com/stock/IMMB/quote

http://www.otcmarkets.com/stock/IMMB/chart

http://www.otcmarkets.com/stock/IMMB/news

http://www.otcmarkets.com/stock/IMMB/filings

[mcmoon]

1 year 5 years
Immunotech Laboratories Inc:
1 week:
+133.33%

1 month:
+250.00%

6 months:
+75.00%

1 year:
+58,233.33%

Quelle:
http://markets.ft.com/research/Markets/Tearsheets/Summary?s=…

[mcmoon]

So... vorangegangen eben ein kurzer Überblick über Immunotech Lab.
Vielleicht finden sich hier ein paar Interessierte die den Weg mit beobachten wollen, sich in einem respektvollen Miteinander über Pro´s und Contra´s austauschen wollen?

Ich jedenfalls bin seit einer Woche in diesem Wert investiert.
Einstiegskurs 0,08 Euro/Cent

[Larry_1]

hmm, 1600% Plus seit Ende Januar

sobald hier die Anschlusskäufer fehlen, rauscht es erstmal 50% runter

und danach... bleibt es abzuwarten, ob weiter down

[mcmoon]

Wie bewertest du die Tatsache, das lediglich 1 Mio Shares im Freefloat sind? Eher positiv oder eine Gefahr?

[mcmoon]

Hier etwas zum Thema "ROI"

http://www.immunotechlab.com/?wpdmact=process&did=Mi5ob3RsaW…

[mcmoon]

Es sieht so aus, als wäre hier in Good Old Germany wirklich noch niemand auf Immunotech aufmerksam geworden?
Darum das gegen Null tendierende Feedback hier? :-)

Ich könnte mir allerdings gut vorstellen, dass sich dies bald ändern wird. Ich jedenfalls, lasse mich überraschen, wohin die Reise heute geht an der OCT

[mcmoon]

Im Amiland ist es an vielen Stellen im Radar, so auch hier eine ganz treffende Zusammenfassung, warum es vielleicht wirklich ein Geheimtipp ist:

http://investorshangout.com/post/568297/-IMMB-gt-gt-gt-MUST-…

[mcmoon]

... und für alle, die es weniger reißerisch mögen als in ihub etc.

Auch hier sind alle wichtigen Facts auf einen Blick:

http://finance.yahoo.com/q?s=IMMB

[mcmoon]

und wieder eine echt klasse News, brandaktuell:

Immunotech Laboratories Appoints New Chief Financial Advisor to Strengthen Company's Growth and International Expansion Plan

PASADENA, Calif., Feb. 7, 2013 /PRNewswire via COMTEX/ -- Immunotech Laboratories, Inc. (PINKSHEETS : IMMB )

Immunotech Laboratories, Inc., today announced the appointment of Mr. Valentin Dimitrov to the company Board of Directors as Chief Financial Advisor effective immediately.

Mr. Dimitrov (48) has an impressive professional history in the International Pharmaceutical World along with an impressive background in the formation and management of International Corporations, including the founding member and supervisory Board Chairman of the International Orthodox Bank - (present "Investbank" JSC).

Immunotech Director Bo Linton, further commented Mr. Dimitrov has an extensive knowledge of the Immunotech "IPF" patented technology and has worked alongside the company for several years, assisting with International awareness and potential Clinical Trial progression for the company's Immunotherapy Treatments.

Immunotech President Harry Zhabilov commented, "We are very pleased to announce the appointment of Valentin to the Board of Directors and feel he will be a valuable member of our team, and significantly help accelerate the progression of the company towards FDA approval for the 'IPF' technology."

The appointment of Mr. Dimitrov to Immunotech's Board of Directors helps with the potential goal of upgrading the company to the NASDAQ exchange, where a minimum of 5 Board Members are required.

About Valentin Lordanov Dimitrov

EDUCATION:
Kliment Ohridski University Master's degree - Social Pedagogics

Kiev State University, Ukraine Bachelor of International Diplomatic Relations

SPECIALIZATIONS:
1995: University of National and World Economy - Sofia - Finances

1999: Chemical-technological University - Sofia - Organic chemistry

LANGUAGES: English - Fluent , Russian - fluent , German - spoken

PROFESSIONAL BACKGROUND:
2007-Current: "Vital-Fe" LTD - Distribution of bio-technology and pharmaceutical products - Director

2003-Present "Bulgarian Association of Chemical and Fertilizer Industry" - Chairman

2002-2003 "Chimco Vienna" GmbH - Distributor of chemical and pharmaceutical products - Director

1999-2002 "CHIMCO" JSC, Vratza - Chemical production plant - Chairman of the Board of Directors

1992-1998 "Prima Gas" JSC - supply of natural gas - Director

1995-1996 "International Orthodox Bank" - (present "Investbank" JSC), Founder and member of the Supervisory Board

1994-1995 "Private Agricultural and Investment Bank" - Member of the Supervisory Board

1990-1991 "Pharmachem" JSC - pharmaceutical and chemical industry - Director of Department

Safe Harbor Statement: This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Immunotech Laboratories, Inc. from time to time in its periodic reports filed with the SEC. IPF is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Immunotech Laboratories believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Immunotech Laboratories to establish the efficacy of IPF in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of IPF in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, Immunotech Laboratories or any other person that the objectives and plans of Immunotech Laboratories will be achieved should not regard the forward-looking statements as a representation.

Company Contact:[e-mail]

Investor Relations:The Nabors Group: 713-875-9200E-mail: [e-mail]/Naborsgroup

CSNNewswire - Be Seenwww.csnnewswire.com

nachzulesen auch unter: http://www.otcmarkets.com/stock/IMMB/news

[mcmoon]

Diese PR-News steht auch bei Reuters:

http://www.reuters.com/article/2013/02/07/ca-immunotech-cfa-…

[Larry_1]

Zitat von mcmoon: Wie bewertest du die Tatsache, das lediglich 1 Mio Shares im Freefloat sind? Eher positiv oder eine Gefahr?

Diese ist sogar eine große Gefahr.

Sowas lege ich mir auf keinen Fall ins Depot, vorallem nicht nach dem Megaanstieg innerhalb von Tagen

[mcmoon]

Das würde ich generell schon auch so sehen, allerdings gehe ich davon aus, dass Bo Linton schluß macht mit OTC-Gezocke.
Sein Ziel, das er auch in dem Video anspricht... Er möchte Immunotech an einem anderen Börsenplatz haben! Nasdaq oder NYSE

[mcmoon]

Speziell dieses Thema wurde auch schon mal in Investorshub gepostet, bzw die Anforderungen, die nötig wären um auf einen vernünftigen Börsenplatz zu kommen:

http://investorshub.advfn.com/boards/read_msg.aspx?message_i…

[mcmoon]

So wie es aussieht, scheint die 0,35$ eine Marke sein, die es zu überwunden gilt. Auch gestern ist hier der Kurst schon einmal abgeprallt. Mal sehen, wo es heute noch hingeht?

[mcmoon]

Wieder ein schönes Plus heute!
Vielleicht wirklich der Beginn einer richtig "netten" Story?
Auch wenn ich mir der Risiken, die in diesem Wert liegen vollkommen bewußt bin, sehe ich viele positive Zeichen

[mcmoon]

zut Info:

http://www.barchart.com/cheatsheet.php?sym=IMMB

[mcmoon]

Worum geht es? Auch hier zu lesen:

http://xplosivestocks.com/immb-medical-science-play-could-be…

[mcmoon]

oder auch hier... Immunotech ist im Focus:

http://www.bio-medicine.org/medicine-technology-1/Immunotech…

[mcmoon]

LOI – Zusammenarbeit mit einem international agierenden Bio-Tech Partner:

https://research.tdwaterhouse.ca/research/public/Stocks/News…

[mcmoon]

http://research.tdwaterhouse.ca/research/public/Stocks/NewsA…

[mcmoon]

HIV/AIDS... darum geht es.Hat hier vielleicht Immunotech – mit dem angesprochenen Letter of Intent – die "Finger im Spiel"?

http://allafrica.com/stories/201302070388.html

Die nahe Zukunft wir es sicher zeigen

[Eberhard01]

Antwort auf Beitrag Nr.: 44.118.612 von mcmoon am 08.02.13 12:50:51

Genieße deinen Monolog und erfreue dich an der Ruhe in deinem thread.

[mcmoon]

Hier die News zur Ernennung des neuen Finanz-Direktors Lordanov Dimitrov inkl. Vita:

http://www.bizjournals.com/prnewswire/press_releases/2013/02…

[mcmoon]

auch hier zu lesen:

http://www.bio-medicine.org/medicine-technology-1/Immunotech…

[mcmoon]

Die letzen Tage können sich sehen lassen :-)

Date Shorted High Low Close Chg ShortVol RegularVol
Feb 08 3.06% 0.40 0.25 0.39 -2.50% 1,265 41,380
Feb 07 15.25% 0.40 0.34 0.40 +14.29% 10,035 65,782
Feb 06 17.82% 0.35 0.22 0.35 0.00% 11,408 64,022
Feb 05 23.90% 0.45 0.27 0.35 +59.09% 23,699 99,144
Feb 04 21.25% 0.28 0.18 0.22 +15.79% 18,753 88,245
Feb 01 19.11% 0.19 0.15 0.19 +26.67% 5,390 28,205
Jan 31 21.99% 0.15 0.11 0.15 +15.38% 10,200 46,375
Jan 30 12.46% 0.13 0.06 0.13 +1200.00% 19,222 154,222

[mcmoon]

Gestriger, heftiger Rücksetzer tat weh... aber wahr wahrscheinlich auch nötig. Es bleibt spannend, wohin die Reise geht

[mcmoon]

Breaking News: Video Interview With Harry Zhabilov of Immunotech Laboratories Inc.:

http://youtu.be/oPFso7SiCYs

Topics discussed with Harry Zhabilov include the addition of new board members, goals of up-listing to NASDAQ, the FDA, and how the immunotherapy treatment works.

[mcmoon]

und wieder eine klasse News!!

http://www.otcmarkets.com/stock/IMMB/news

[mcmoon]

Die News auch bei Reuters:

Immunotech Laboratories Receives $2M Funding Approval To Begin European
Clinical Trials Testing For Company's Patented "IPF" HIV-AIDS Medicines

http://www.reuters.com/article/2013/02/13/ca-immunotech-labs…

[mcmoon]

klingt alles vielversprechend:

"Many biotechnology companies are striving to develop new therapeutics for HIV/AIDS to provide more biological- and cost-effective treatments. Looking to establish a footprint in the industry is little Pasadena, California-based Immunotech Laboratories, Inc. (Pink Sheets:IMMB) with its proprietary proteins for treating infectious diseases.

The company’s flagship compound, ITV-1 (Immune Therapeutic Vaccine-1), is a suspension of Inactivated Pepsin Fraction, or IPF, which studies have shown is effective in the treatment of HIV/AIDS. IPF, a purified extract of porcine pepsin, is known to modulate the immune system.

Still in early stages of development of its immunotherapeutic treatments, Immunotech has initially set its sights on HIV/AIDS, although it has said that it intends to pursue other prominent indications, such as cancer, in the future.

In order to control costs and expedite development of ITV-1, the company is taking its initial clinical trials to Bulgary, a country where the father of Immunotech founder and president Harry Zhabilov was a prominent researcher at the Bulgarian Academy of Sciences. The elder Zhabilov was also focused on “manipulating the immune system to fight HIV/AIDS,” according to Zhabilov’s blog on tumblr.com. The Immunotech president seems to have quite a lengthy lineage in the immune system arena.

Whether that will translate to the commercialization of a new therapy is still years away, but it took a step in the right direction with news today that the company has secured $2 million in funding from Bulgarian-based partner Immunotech BG to begin clinical trials in advanced-stage AIDS patients.

50 patients are scheduled to be enrolled in the trials which will be hosted at “two of the largest Bulgarian hospitals” testing the U.S. company’s patented IPF-ITV and IPF-ITV Phases, the company said in today’s statement.

"We believe that in both cases, the results will be very encouraging, as to this point we have already applied the medicine with volunteers and the results have been highly successful in Bulgaria, where the use of the vaccine labeled as an 'Experimental Drug' is permitted,” said Bo Linton, director at Immunotech.

Linton said he believes the clinical trials in Bulgaria, which are only slated to last from March 2013 to August 2013, will provide data that will significantly help the company’s quest for a “Fast Track” designation from the U.S. Food and Drug Administration.

Shares of IMMB have historically been very thinly traded, but have seen an incremental volume increase over the past two weeks with shares rising from around a dime to as high as 45 cents. Shares have cooled from those highs to be trading on Wednesday at 25 cents, with an intraday high of 32 cents and about 57,000 shares in volume.

Proper due diligence of this developmental biotech is, as always, encouraged.

Copyright © 2013 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Nachzulesen unter:
http://www.allpennystocks.com/aps_us/special-reports/334/imm…

[mcmoon]

Hier die neueste News:

" Immunotech Laboratories Inc. Announces Clinical Trials Updates For Company's AIDS-HIV "IPF" Medicines

PASADENA, Calif., Feb. 20, 2013 /PRNewswire via COMTEX/ -- Immunotech Laboratories, Inc. (PINKSHEETS: IMMB) Today announced the following updates for the International Clinical Trials of the company's patented AIDS-HIV "IPF" Medicine(s).

Immunotech Founder and President Harry Zhabilov today announced the progress with the project IPF-ITV-1 in the European Union. Mr. Zhabilov stated: "We have negotiated with two of the biggest hospitals in Bulgaria (thus, European Union) to carry our clinical trials of IPF-ITV-1 and ITV-2 as follows:

At the Infectious Disease Hospital, Sofia, with Hospital Director Prof. Cherveniakova we will carry out clinical trials of ITV-1 with 50 patients infected with HIV-AIDS in its most advanced stage.

At the Military Hospital, Sofia, with Hospital Director Prof. General Stoyan Tonev we will carry out clinical trials of ITV-2 with 50 patients ill with chronic hepatitis in its most advanced stage." The clinical trials will be conducted parallel with protease inhibitor.

Mr. Zhabilov further stated: "We believe that in both cases, the results will be very good, because in Bulgaria until this point, we have already applied the experimental labeled "IPF" Medicine with HIV infected volunteers and the outcomes to date have been extremely successful."

Immunotech recently completed negotiations in the Republic of Macedonia with Bionika Pharmaceuticals who agreed to carry out clinical trials of IPF-ITV-3 with 50 patients ill with HCV using the "IPF" labeled Experimental Drug Medicines.

The clinical trials in Bulgaria (Referred to as, EU) are scheduled to begin in March 2013 and end in August 2013, which will give Immunotech, the rights to receive approval for huge applications of the "IPF" Medicines. In this respect, Immunotech has had a series of conversations with Mr. Vladimir Stoichev, the Deputy General Director from Sopharma Bulgaria, and the parties have reached agreement for the signing of a contract between Immunotech Laboratories BG and Sopharma for joint production of IPF-ITV.

Sopharma is a leading pharmaceutical company in the European Union.

RELEVANT ARTICLES & LINKS FOR AIDS-HIV MEDICINES

http://news.yahoo.com/gsk-wins-priority-status-hiv-drug-u-16…

About Immunotech Laboratories Immunotech Laboratories is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases such as HIV, Cancer, Hepatitis and Aids. www.immunotechlab.com

Safe Harbor Statement: This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Immunotech Laboratories, Inc. from time to time in its periodic reports filed with the SEC. IPF is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Immunotech Laboratories believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Immunotech Laboratories to establish the efficacy of IPF in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of IPF in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, Immunotech Laboratories or any other person that the objectives and plans of Immunotech Laboratories will be achieved should not regard the forward-looking statements as a representation.

Company Contact: [e-mail]

Investor Relations: The Nabors Group: 713-875-9200E-mail: [e-mail]/Naborsgroup

SOURCE Immunotech Laboratories, Inc. "

http://www.otcmarkets.com/stock/IMMB/news

[mcmoon]

Clinical Trials in Bulgarien gestartet:

http://www.ad-hoc-news.de/immunotech-laboratories-inc-announ…

[mcmoon]

Analyst Report auf die obige News:

http://www.stockhouse.com/news/usreleasesdetail.aspx?n=87416…

[mcmoon]

und heute eine wahrlich gute News.... und das Volumen verdreifacht:

http://www.otcmarkets.com/stock/IMMB/news

[mcmoon]

... mittlereile hat es sich sogar verzehnfacht gegenüber den mittleren Ständen der letzten Monate. Die News scheint Wirkung zu zeigen.

[mcmoon]

Ein sehr wichtiger Schritt in die richtige Richtung!

Immunotech Laboraties Retains The Lebrecht Group to Upgrade the Company to Fully Reporting Status

MONROVIA, CA, Apr 08, 2013 (Marketwired via COMTEX) -- Immunotech Laboratories, Inc. (PINKSHEETS: IMMB) today announced the company signed an agreement with The Lebrecht Group, a professional law corporation, to provide legal services for Immunotech and to upgrade the company to OTC:BB fully reporting current status.

Immunotech Founder, President & Chief Scientific Officer Harry Zhabilov today commented, "This step will help assure our investors and shareholders of the forward progression of Immunotech in both the Medical and Investment communities."

This information is filed on the www.sec.gov website as an official 8K filing.

Further information about Immunotech's patented "IPF" can be obtained from www.immunotechlab.com

This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Immunotech Laboratories, Inc. from time to time in its periodic reports filed with the SEC. IPF is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Immunotech Laboratories believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Immunotech Laboratories to establish the efficacy of IPF in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of IPF in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, Immunotech Laboratories or any other person that the objectives and plans of Immunotech Laboratories will be achieved should not regard the forward-looking statements as a representation.

Company Contact:
Immunotech Laboratories, Inc.
Email Contact

Public Relations
The Nabors Group:
713-875-9200
E-mail: Email Contact
www.facebook.com/Naborsgroup


SOURCE: Immunotech Laboratories, Inc.

CONTACT: http://www2.marketwire.com/mw/emailprcntct?id=BC9BC1DBC8D7C5…
http://www2.marketwire.com/mw/emailprcntct?id=69899E80408B9E…

[mcmoon]

NEWS!![/b]
Es wird immer interessanter!

http://www.otcmarkets.com/stock/IMMB/news

[mcmoon]

Hier ein heutiger Börsenbrief.... sehr ausführlich und informativ:

Good Evening Subscribers, tonight's Special Report is on IMMB

IMMB is a company at the forefront of Immunotherapy Treatments.


IMMB (Immunotech Laboratories) is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. IMMB is committed to creating drugs for the better health of mankind.

IMMB strives to become a leader in immuno-therapeutic treatment and prevention of HIV/AIDS, Cancer and other immuno related disorders

After decades of research, IMMB determined that it was time to take Immunotech Laboratories, Inc. (formerly International Technology Systems, Inc.) and their product to the next level.

IMMB’s flagship compound ITV-1 (Immune Therapeutic Vaccine-1) is a suspension of Inactivated Pepsin Fraction (IPF), which studies have shown is effective in the treatment of HIV/AIDS.

IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system.


IMMB Products

Irreversible Pepsin Fraction (IPF)

Irreversible Pepsin Fraction (IPF) is a platform technology that can be used to facilitate a broad range of applications. It is free from neurological, gastrointestinal and hematological side effects seen in the anti-retrovirals in use today. IPF has not shown to be subject to viral resistance and is cost effective.

IPF Advantages over Antiretrovirals

Current Antiretroviral Therapies Have Serious Limitations: HIV infections are most treatable during its earlier stages but cannot take antiretrovirals during earlier stages, since drug resistance so often develops. Which means limited or no treatment options when viral load and CD4 cell counts are at their worst, i.e., AIDS. Non-antiretroviral treatments like Immunotech IPF remain lacking but are in tremendous demand.


IMMB's therapy is:

• Unique, patent-protected HIV/AIDS therapy

• Turns on the immune system to fight HIV infections ― not achieved with other therapies

• Inhibits the infection of CD4 T-cells by HIV

• Raises CD4 T-cell counts to healthier levels

• Reduces HIV viral loads

• Replaces or complements current antiretroviral therapies

• Potentially lesser costly and much less toxic

• May be effective as a periodic therapy instead of a daily one

• Likely unaffected by HIV mutations that can hamper antiretroviral therapies (HAART)

How does IPF work? 2 modes of action:

1. Directly prevents HIV from infecting CD4 T T-cells

2. Activates the Th1 immune response, i.e., turns on macrophages that actually ingest HIV itself, killer T actually T-lymphocytes that destroy HIV HIV-infected cells and other HIV cells HIV-fighting immune system responses
Currently it’s the only HIV/AIDS therapy to achieve this.

MODE 1

By binding to specific proteins on the outer surface of HIV particles, Immunotech IPF directly prevents HIV from infecting CD4 T T-cells.

MODE 2

Immunotech IPF binds to T-cells and turns on Th1 immune system responses that kill HIV and HIV- infected cells.

This is not done by any other HIV/AIDS therapies.

Treatments for HIV patients are low cost:
less than 500 per treatment and only 3 treatments are necessary.

IMMB recently announced Breakthrough Results for HIV and AIDS Treatment for Terminal Salvage Patients

Pursuant to significantly positive results with its patient population targeting full blown AIDS patients, IMMB has completed numerous clinical contracts with Mexican hospitals to initiate a full blown effort of clinical trial protocol preparation for its HIV/AIDS Vaccine drug candidate.

The successful outcome of these efforts will eventually provide the necessary regulatory means for its product's registration approval in the Republic of Mexico and eventually open a venue to most of the central and South American markets.

Resistance to all commercially available antiretroviral (ARV) agents within all classes has been reported.

The occurrence of multi-class resistance remains high, with 20% of infected individuals developing resistance to two or more classes within six years of initiating treatment, and 10% of newly diagnosed infections already resistant to at least one class in the U.S. Multi-class resistance is even more prevalent in disenfranchised patient populations, whose rates of successful adherence to even the most simplified regimens available remains prohibitively low.

Inactivated Pepsin Fraction (IPF), like other natural autoantibody based fractionated proteins, has an affinity to pathogenic binding and simultaneously produces effects of immune homeostasis.

IPF has shown significant antiretroviral activity via immune stimulatory pathways in vitro, notably helper T1 cells elaborate cytokines INFy, IL-2. These cells selectively promote cell-mediated immune responses that are disadvantageous to viral replication.

IMMB's Patented "IPF" Technology A Serious Contender In The Race For HIV & Cancer Cures

Company Director Mr. Bo. Linton of IMMB recently stated Immunotech's technology is now considered a major contender in the race for HIV & Cancer cures.

Mr. Linton further commented the company recently received an initial inquiry for a significant order of the company's patented HIV vaccine by an International associate for use as an "Experimental Drug".

If confirmed the initial order would be in excess of several Million Dollars. This would expand the company's operations from Research & Development to a Bio-Pharma manufacturing company.

In Africa, where approved experimental treatments are permitted, there are approximately 30 Million HIV/AIDS patients alone.

Start your research on IMMB at:http://www.immunotechlab.com/

[mcmoon]

Immunotech Laboratories, Inc. Provides Funding Update

Immunotech in Discussions With New Financing Group

MONROVIA, Apr 29, 2013 (GLOBE NEWSWIRE via COMTEX) -- Immunotech Laboratories, Inc. (Pink Sheets:IMMB) today announced that they are in preliminary discussions with a large potential funding group out of Dubai. The group has shown interest in the future development and support of the Company's future FDA clinical trials.

Blaine Nabors, Vice President of Business Development for Immunotech, stated, "We have had several separate discussions, and an agreement-in-principal will hopefully be reached by the middle of next week. Immunotech's strategic relationships such as this potential one are critical as we strive to further advance our Inactivated Pepsin Fraction (IPF) technology."

About Immunotech Laboratories

Immunotech Laboratories, Inc. is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Visit www.immunotechlab.com.

Safe Harbor Statement

This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Immunotech Laboratories, Inc. from time to time in its press releases and periodic reports filed with the SEC. IPF is not approved by the U.S. Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Immunotech believes that the forward-looking statements and underlying assumptions contained herein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Immunotech to establish the efficacy of IPF in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of IPF in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, no person should consider the forward-looking statements herein as a representation.

Actual results could differ materially from current projections or implied results. Immunotech Laboratories, Inc. undertakes no obligation to revise these statements following the date of this news release.

CONTACT: Company Contact

[e-mail]
Blaine Nabors: 713-875-9200
E-mail: [e-mail]

http://media.globenewswire.com/cache/25850/small/19340.jpg

http://www.globenewswire.com/newsroom/ti?nf=MTMjMTAwMzAyNjMj…

(C) Copyright 2013 GlobeNewswire, Inc. All rights reserved.

-0-

KEYWORD: MONROVIA
INDUSTRY KEYWORD: Business Services
SUBJECT CODE: Financing Agreements
BIOTECHNOLOGY
MEDICAL
PHARMACEUTICALS
FINANCING AGREEMENTS

[mcmoon]

Der Tag X kommt näher. Sollte hier wirklich ein Fond in Betracht kommen, dürften wir hier bald ganz andere Kurse sehen!?
Ich denke die News dürfte heute oder morgen über den Ticker laufen.
Lassen wir uns überraschen ;-)

[mcmoon]

ist das der Durchbruch... der Tag X?

NEWS
http://www.otcmarkets.com/stock/IMMB/news

[mcmoon]

Hier die Komplette NEWS:

Immunotech Laboratories Signs Funding Agreement With Curing Capital, Inc.

MONROVIA, May 28, 2013 (GLOBE NEWSWIRE via COMTEX) -- Immunotech Laboratories, Inc. (Pink Sheets:IMMB) Immunotech Laboratories, Inc. today released the following company updates for shareholders and Investors:

Immunotech Founder, President & Chief Scientific Officer, Harry Zhabilov today stated, "The company signed a funding agreement with 'Curing Capital, Inc.' an established Capital Venture Company with over 100 years combined Banking and Investment experience by the company's management Team."

Curing Capital, Inc. will provide the following services in its role as investment consultant.

Assistance in developing and updating a comprehensive Business Plan and Executive Summary.

Additionally Curing Capital will provide best efforts to introduce funding sources whose goal will be to secure up to $30,000,000 in long term financing through equity, or debt, or combination of both equity and debt. For Immunotech Laboratories, Inc.

Mr. Zhabilov further commented, "This is a positive breakthrough for Immunotech's continued Research and Treatment development of Terminal diseases such as the Aids & HIV virus."

Further information about Immunotech's patented "IPF"can be obtained from www.immunotechlab.com

About Curing Capital,Inc

Curing Capital is a consulting firm that specializes in introducing private and public companies to a network of funding sources ranging from Venture Capitalists (VCs), Investment Bankers (IBs) to Angels and High Net Worth Investors. We have also helped companies with other financial requests such as business plan development, Investor Relations, Public Relations, 211 filings and preparing private companies who wish to go public. The Curing Capital team has over 100 years of investment banking experience combined. www.curingcapital.com

This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Immunotech Laboratories, Inc. from time to time in its periodic reports filed with the SEC. IPF is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Immunotech Laboratories believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Immunotech Laboratories to establish the efficacy of IPF in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of IPF in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, Immunotech Laboratories or any other person that the objectives and plans of Immunotech Laboratories will be achieved should not regard the forward-looking statements as a representation.

CONTACT: Company Contact: [e-mail]
Public Relations:
The Nabors Group: 713-875-9200
E-mail: [e-mail]
www.facebook.com/Naborsgroup

http://media.globenewswire.com/cache/25850/small/19340.jpg

http://www.globenewswire.com/newsroom/ti?nf=MTMjMTAwMzQxNTQj…

(C) Copyright 2013 GlobeNewswire, Inc. All rights reserved.

-0-

KEYWORD: MONROVIA
INDUSTRY KEYWORD: Biotechnology
SUBJECT CODE: Financing Agreements
BIOTECHNOLOGY
FINANCING AGREEMENTS

[mcmoon]

der Vollständigkeit halber, auch wenn sich hier im Moment 0,0 tut die letzte News:

Immunotech Laboratories, Inc. Announces the Results From Gap Analysis Report

MONROVIA, Jun 19, 2013 (GLOBE NEWSWIRE via COMTEX) -- Immunotech Laboratories, Inc. (Pink Sheets:IMMB) today announced the results from Gap Analysis report.

Immnuotech President Harry Zhabilov and Vice President of business development Blaine Nabors announced the results from the Gap Analysis report. This report is the first step in the moving towards FDA clinical trials for Immunotech Laboratories.

IND Directions' Dr. Patricia Williams has conducted a gap analysis with the objective of identifying areas that require more information on IPF for the Pre-IND and IND submissions to FDA. The materials reviewed included general product technology overviews, meeting abstract, technical information on the peptide structure and manufacturing, and a protocol for a pilot clinical trial conducted in Mexico.

Dr. Williams reports that Zhabilov's IPF platform proposed mechanism of action represents a novel approach for the treatment of HIV via inhibition of HIV infection (i.e. blocking attachment and entry into T-cells) and stimulating cell-mediated immunity. Additional studies in cell culture and in animals were recommended to further document IPF's mechanism of action and efficacy against HIV.

Zhabilov and Mr. Nabors stated that Immunotech Laboratories is now preparing for the Pre-IND studies that will begin by the end of this year and be subsequently presented to the FDA. Mr. Nabors said "We strive to provide further advancements of Immunotech Inactivated Pepsin Fraction "IPF"

About Immunotech Laboratories

Immunotech Laboratories is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases such as HIV and AIDS. www.immunotechlab.com

Safe Harbor Statement: This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Immunotech Laboratories, Inc. from time to time in its periodic reports filed with the SEC. IPF is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Immunotech Laboratories believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Immunotech Laboratories to establish the efficacy of IPF in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of IPF in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, Immunotech Laboratories or any other person that the objectives and plans of Immunotech Laboratories will be achieved should not regard the forward-looking statements as a representation.

CONTACT: Company Contact:
VP of Business Development
Blaine Nabors : 713-875-9200.
E-mail: [e-mail]

http://media.globenewswire.com/cache/25850/small/19340.jpg

http://www.globenewswire.com/newsroom/ti?nf=MTMjMTAwMzY4MzQj…

(C) Copyright 2013 GlobeNewswire, Inc. All rights reserved.

-0-

KEYWORD: MONROVIA
INDUSTRY KEYWORD: Biotechnology
SUBJECT CODE: Research Analysis and Reports
PHARMACEUTICALS
BIOTECHNOLOGY

[mcmoon]

Hier eine interessante News von heute:

Amarantus Appoints David A. Lowe, PhD to Board of Directors

Company Concurrently Appoints NeuroAssets to Lead MANF Development

SAN FRANCISCO, Nov 06, 2013 (GLOBE NEWSWIRE via COMTEX) -- Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to neurodegeneration and apoptosis, today announced the appointment of David A. Lowe, PhD to its Board of Directors. Dr. Lowe comes to Amarantus with over 35 years of experience in central nervous system (CNS) drug discovery and development within the biopharmaceutical industry, where he has served in senior roles with various major biopharmaceutical companies, as well as emerging biotechnology companies. Concurrently, Dr. Lowe's advisory firm, NeuroAssets Sarl, which has development expertise within the areas of neurology, endocrinology and ophthalmology, will be overseeing the translational development of MANF through first-in-man clinical studies, as well as advising on the development of the LymPro Test(R) blood diagnostic for Alzheimer's disease, PhenoGuard Protein Discovery Engine and potential additions to the Amarantus portfolio.

"It has become clear with the number and quality of peer-reviewed publications over the last two years that MANF plays an emerging and significant role in human biology, giving rise to various therapeutic development opportunities in the CNS and beyond," said David A. Lowe, PhD, Amarantus' newly appointed member of the Board of Directors. "Going forward, we intend to complete the process of reprioritizing the MANF pipeline, with a strong focus on orphan indications. I believe there is a significant opportunity to develop MANF in an orphan indication, and thereafter pursue a label-expanding exercise to address the various medical conditions MANF may ultimately end up treating. We continue to believe that Parkinson's disease (PD) is a very attractive therapeutic application for MANF given the data produced to date. However, orphan indications such as Retinitis Pigmentosa present a tremendous opportunity to speed the time to market for MANF, thereby increasing its net present value at the same time as facilitating success in PD and other indications that have more complicated regulatory pathways. I am very excited with the opportunity to take on a formal role with Amarantus at this time as the Company has made significant corporate progress over the last year and is poised for significant growth as we move forward."

"We believe we have scored a major coup in adding Dr. Lowe's tremendous expertise and deep industry connections to the team at Amarantus," said Gerald E. Commissiong, President & CEO of Amarantus. "With this critical addition to our Board of Directors, and the appointment of NeuroAssets to oversee the reprioritization and translational development of MANF, we have a great deal of confidence that we are putting our therapeutic program in the hands of a skilled and experienced team, capable of unlocking the true value of our lead therapeutic asset through judicious product development, as well as properly positioning MANF with major pharmaceutical companies and Wall Street analysts within the competitive landscape."

Dr. Lowe is President & CEO of NeuroAssets, Sarl, a Swiss-based neuroscience-focused consulting firm, providing advisory services to pharmaceutical, venture capital and biotechnology companies throughout the world. Dr. Lowe previously served as the Chief Scientific Officer of Psychogenics, Inc. and before that as Director and Chief Scientific Officer of Memory Pharmaceuticals, Inc., a biotechnology company pursuing innovative treatments for Alzheimer's and Schizophrenia. Prior to Memory Pharmaceuticals, Dr. Lowe served as the Executive Vice President and Chief Scientific Officer at Fidelity Biosciences Group, Fidelity Investments in Boston, MA, an investment firm focused on the healthcare industry. He also served as President, CEO and Director of Envivo Pharmaceuticals, a Fidelity-funded pharmaceutical company pursuing new treatments for Alzheimer's disease now in Phase 3 development. Dr. Lowe also served as Vice-President and Therapeutic Area Head, Central Nervous System, at Roche Pharmaceuticals, Vice President & Global Therapeutic Area Head of Central Nervous System Research at Bayer AG., and Head of CNS Biology and Deputy Head of CNS Research at Sandoz Ltd (now Novartis). Dr. Lowe received his PhD in neurobiology from the University of Leeds, UK.

About NeuroAssets

NeuroAssets' mission is to enhance and mature the medical and financial value of novel preclinical and clinical-stage drugs and devices for treating or diagnosing diseases of the nervous system ("neuro assets"). The Company provides strategic guidance and operational management to existing companies with such assets, or helps in the creation of start-ups to develop assets in the neuro field. Where necessary, NeuroAssets connects neuroscience projects with financing opportunities.

To achieve these goals NeuroAssets uses its own broad scientific R&D experience, expertise and wide international networks in the pharma, biotech, academic, business and financial worlds. NeuroAssets performs technology evaluations, R&D project analysis and planning, management of preclinical and clinical CROs, and patenting. It advises its clients on drug discovery and development projects through to clinical trials, working with a global network of consultants having industry expertise in the required specialties such as pharmacology, chemistry, preclinical and clinical development, regulatory affairs, patenting etc.

Through its connections with venture capitalists, financial institutions, and private individuals, NeuroAssets matches client companies and their projects with investors, with the aim of financial exits such as an asset license, sale, or company acquisition.

About Amarantus

Amarantus is a development-stage biotechnology company focused on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Alzheimer's disease, Traumatic Brain Injury, and other human diseases. The Company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test(R)") for Alzheimer's disease and owns the intellectual property rights to the therapeutic protein Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for various protein folding-related medical conditions. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), in collaboration with Brewer Sports International raising awareness of new products in development for concussions and traumatic brain injury. The Company also owns intellectual property for the diagnosis of Parkinson's disease ("NuroPro") and the discovery of neurotrophic factors ("PhenoGuard"). Amarantus operations are located at Janssen Labs @QB3 in San Francisco, CA. For further information please visit www.Amarantus.com, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.

CONTACT: Investor/Media Contacts

Russell Miller, Director of Investor Relations
Amarantus Bioscience Holdings, Inc.
408.737.2734 x 109
[e-mail]

http://media.globenewswire.com/cache/27474/small/21277.jpg

http://www.globenewswire.com/newsroom/ti?nf=MTMjMTAwNTY0NzQj…

(C) Copyright 2013 GlobeNewswire, Inc. All rights reserved.

-0-

KEYWORD: SAN FRANCISCO
INDUSTRY KEYWORD: Healthcare & Medical Services
SUBJECT CODE: Directors and Officers
BIOTECHNOLOGY
PHARMACEUTICALS
MANAGEMENT CHANGES

[mcmoon]

und wer wmehr über David A. Lowe wissen will, hier ein Link:

http://www.ljmu.ac.uk/LAW/91999.htm

[mcmoon]

oha, ich mehrke gerade, bin im falschen Thread! Sorry

[mcmoon]

Endlich auch hier mal eine News:

http://www.otcmarkets.com/stock/IMMB/news

Vielleicht hilft das Vertrauen in diesen Wert zu bringen... vielleicht gar ein Uplisting?

[mcmoon]

endlich mal wieder up.... 49,25%
wurde auch Zeit, dass sich hier etwas bewegt :-)

[mcmoon]

Ich fasse es nicht... hier kommt echt wieder Leben rein :-)

[mcmoon]

0,06 +185,71%
so kann es weiter gehen!

[mcmoon]

langsam kommt hier wieder Leben rein :-)
+222%

[mcmoon]

Doe 0,10 am Freitag getestet!!! Das war hier schon lange nicht mehr der Fall. Ich denke, da ist was im Busch

[mcmoon]

Real-Time Best Bid & Ask
0.03 / 0.25

Bahnt sich hier was an??

[mcmoon]

Hier ist was im Busch.... nur die Frage was?
Keine News, keine PR... weit und breit nichts!
Aber soweit ich mich erinnere gabs klinische Test irgendwo in Bulgarien?? Vielleicht kommt aus der Seite eine News?

[mcmoon]

75% Plus heute... was will man mehr :-)

[mcmoon]

gehts heute über die 0,10?
Gibt es einen Ausbruch, wie letzes Jahr?

Ich weiß, ich rede hier mit mir selbst :-) Macht nichts, dann streiche ich die Gewinne alleine ein ;-)

[mcmoon]

heute mal wieder 196%+ wohin geht die Reise?
Langsam wäre es aber auch echt Zeit mit einer Meldung der Firmenführung!

[mcmoon]

Sieht nett aus, heute 23.900% im Plus gratulation an denjenigen, der vorgestern das Glück hatte, 4000 Shares zu 0,0001 zu ergattern

[mcmoon]

Ich wollte ne Mio zu dem Preis, bin aber natürlich nicht bedient worden. Schade eigentlich:-)

[mcmoon]

Klasse News heute:

http://de.advfn.com/p.php?pid=nmona&article=63400686&xref=ne…

[mcmoon]

Bis jetzt, haben's noch nicht mal die Amis geschnallt